NCT06460298 - ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

October 1, 2026

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

ProAgio Dose Levels (DL) 1,2,3,4

ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.

DRUG

ProAgio Dose Expansion

ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.

Trial Locations (2)

RECRUITING

Emory University Winship Cancer Institute, Atlanta

NOT_YET_RECRUITING

Winship Cancer Institute of Emory University, Atlanta

All Listed Sponsors

collaborator

Emory University

OTHER

collaborator

Georgia State University

OTHER

lead

ProDa BioTech, LLC

INDUSTRY